Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,962.00
  • Today's Change-35.00 / -1.75%
  • Shares traded192.56k
  • 1 Year change+6.86%
  • Beta0.8976
Data delayed at least 20 minutes, as of Jul 11 2025 16:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.

  • Revenue in GBP (TTM)2.34bn
  • Net income in GBP265.95m
  • Incorporated2005
  • Employees9.31k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 207 399 2760
  • Fax+44 207 399 2761
  • Websitehttps://www.hikma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Axsome Therapeutics Inc320.10m-206.12m3.97bn683.00--100.81--12.42-5.77-5.778.951.080.75662.313.29632,733.50-48.72-59.62-73.77-80.3291.49---64.39-134.061.96-34.420.7784--42.53---20.05--75.71--
Beijing Tiantan Biological Products Corp633.16m152.58m4.02bn5.30k26.483.42--6.340.74240.74243.095.760.3950.840620.211,156,602.0013.0011.9318.4116.7951.5250.6932.9229.693.63--0.008616.2416.4412.9439.5820.4515.1923.56
Ono Pharmaceutical Co Ltd2.45bn251.47m4.04bn4.29k15.140.968110.441.65106.52106.521,036.361,665.600.49242.403.79113,569,200.005.0710.785.8512.3769.6173.2310.3021.232.56142.590.156936.33-3.1410.73-60.89-3.47-18.6612.20
Richter Gedeon Vegyeszeti Gyar Nyrt1.90bn518.34m4.12bn11.76k7.801.396.702.161,306.971,306.974,799.487,338.150.57581.313.8174,690,570.0015.6813.5517.3515.3568.7560.7927.2422.343.08--0.015640.476.5111.0550.6138.398.6251.82
Dottikon ES Holding AG358.23m98.18m4.13bn793.0041.564.4234.8311.547.647.6427.8871.790.3030.69524.88485,789.408.318.059.679.2567.3672.3727.4125.671.65--0.1159--18.0717.1330.9526.0623.40--
Rhythm Pharmaceuticals Inc101.38m-128.90m4.21bn283.00--290.55--41.53-2.78-2.782.222.570.42421.028.42483,614.80-52.29-52.46-70.40-61.2289.62---123.28-354.183.13--0.4018--68.06---43.26------
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd7.70bn278.85m4.26bn28.14k16.121.15--0.55321.661.6645.8423.200.93886.074.342,648,377.003.565.336.6710.9515.7718.073.795.281.24--0.323128.87-0.6922.92-30.09-2.32-14.016.32
TG Therapeutics Inc286.20m29.00m4.36bn352.00152.0024.72150.2015.240.2440.2442.401.500.75030.41273.031,143,154.007.60-42.9310.17-52.5587.43--10.13-142.453.042.250.5077--40.80364.5984.52---19.24--
Hikma Pharmaceuticals Plc2.34bn265.95m4.38bn9.31k16.582.5610.651.871.191.1910.467.710.64321.823.63251,178.007.387.1911.1810.0045.8849.3511.4711.870.64567.580.360144.059.777.4588.95-5.884.7910.29
ALK-Abello A/S662.35m108.73m4.57bn2.74k45.507.6032.476.914.284.2826.0825.620.76251.266.442,073,375.0012.526.0115.297.6064.4561.9516.428.440.987557.350.12350.0014.7811.0867.70--50.82--
GlaxoSmithKline Pharmaceuticals Ltd323.57m80.05m4.74bn3.11k59.5028.1655.2714.6654.5154.51220.41115.190.97832.7614.5712,043,720.0024.2015.3043.8125.6662.9056.7024.7416.771.54845.380.0051137.078.563.0657.2353.14-31.0316.00
Data as of Jul 11 2025. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

23.60%Per cent of shares held by top holders
HolderShares% Held
JPMorgan (Suisse) SAas of 01 Jun 202514.01m6.31%
Wellington Management Co. LLPas of 25 Feb 202511.15m5.03%
The Vanguard Group, Inc.as of 01 Jun 20255.76m2.60%
BlackRock Advisors (UK) Ltd.as of 25 Feb 20254.45m2.01%
Mawer Investment Management Ltd.as of 01 Jun 20253.92m1.77%
Royal London Asset Management Ltd.as of 01 Jun 20252.96m1.33%
Invesco Asset Management Ltd.as of 01 Jun 20252.94m1.33%
Polar Capital LLPas of 30 May 20252.66m1.20%
Jupiter Asset Management Ltd.as of 31 Mar 20252.30m1.03%
BlackRock Investment Management (UK) Ltd.as of 01 Jun 20252.21m0.99%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.